The 17 most recent market catalysts affecting $PHVS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44
Guggenheim analyst Debjit Chattopadhyay maintained a 'Buy' rating on Pharvaris and raised the price target from $40 to $44. This action signals increased analyst conviction in the …
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62
Morgan Stanley's analyst Maxwell Skor has maintained an 'Overweight' rating on Pharvaris and significantly raised its price target from $46 to $62. This action signals increased co…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 60
Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65
Leerink Partners, a prominent investment bank, has raised its price target for Pharvaris (PHVS) from $50 to $65 while maintaining an 'Outperform' rating. This action signals increa…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 60
Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65
Wells Fargo analyst Yanan Zhu maintained an 'Overweight' rating on Pharvaris (PHVS) and raised the price target from $55 to $65. This action signals a stronger conviction from the …
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62
RBC Capital's analyst Nevin Varghese has raised the price target for Pharvaris (PHVS) from $52 to $62 while maintaining an Outperform rating. This action signals increased confiden…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79
Citizens analyst Jonathan Wolleben has updated their coverage on Pharvaris, maintaining a 'Market Outperform' rating and raising the price target from $75 to $79. This action signa…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 60
Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $50
Wedbush analyst Laura Chico's decision to maintain an 'Outperform' rating and raise the price target for Pharvaris (PHVS) from $42 to $50 signals increased confidence in the compan…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a 'Buy' rating for Pharvaris (PHVS) and maintained a $60 price target. This action sig…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 95
Why Is Pharvaris Stock Soaring Tuesday?
Pharvaris NV announced overwhelmingly positive topline results from its CHAPTER-3 Phase 3 clinical trial for deucrictibant XR, an oral drug designed to prevent hereditary angioedem…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 95
Pharvaris shares are trading higher after the company announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release tablet for the prevention of HAE attacks.
The successful Phase 3 results for deucrictibant are a game-changer for Pharvaris, validating their drug candidate and paving the way for regulatory submissions and potential marke…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 95
Pharvaris Announces Statistically Significant And Clinically Meaningful Topline Results From Its CHAPTER-3 Pivotal Phase 3 Study Evaluating Deucrictibant Extended-Release Tablet For Prevention Of HAE Attacks; Primary Endpoint And All Secondary Efficacy Endpoints Were Met With Statistical Significance
Pharvaris reported overwhelmingly positive Phase 3 results for its drug deucrictibant XR, meeting its primary endpoint with an 83% attack rate reduction versus placebo and all seco…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52
This filing discloses that RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Pharvaris (PHVS) and raised the price target from $51 to $52. This action sig…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40
Guggenheim analyst Debjit Chattopadhyay maintained a 'Buy' rating on Pharvaris and slightly increased the price target from $39 to $40. This action reflects ongoing analyst confide…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75
Citizens analyst Jonathan Wolleben maintained a 'Market Outperform' rating on Pharvaris and slightly increased the price target from $74 to $75. This action signals continued analy…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
Pharvaris Q2 EPS $(0.81) Misses $(0.74) Estimate
Pharvaris (PHVS) announced its Q2 earnings, reporting a loss of $(0.81) per share, which significantly missed the consensus analyst estimate of $(0.74). This 9.46% miss indicates t…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 55
Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology
Pharvaris announced the publication of a comprehensive review article in 'Clinical Reviews in Allergy & Immunology' that provides an overview of bradykinin B2 receptor biology and …
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55
Wells Fargo analyst Yanan Zhu initiated coverage on Pharvaris (PHVS) with an 'Overweight' rating and a $55 price target. This event is significant for Pharvaris as it marks a major…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.